作者: Cheng‐Huang Shen , Jia‐Jen Shee , Jin‐Yi Wu , Yi‐Wen Lin , Jiann‐Der Wu
DOI: 10.1111/J.1476-5381.2010.00861.X
关键词:
摘要: BACKGROUND AND PURPOSE Bladder cancer is a highly recurrent after intravesical therapy, so new drugs are needed to treat this cancer. Hence, we investigated the anti-cancer activity of combretastatin A-4 (CA-4), an anti-tubulin agent, in human bladder cells and murine orthotopic tumour model.